Stockwinners Market Radar for January 02, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
TSLA... | Hot Stocks20:01 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Tesla (TSLA) announced that in the fourth quarter, it produced 439,701 vehicles, 4% of which are subject to operating lease accounting, and delivered 405,278 vehicles. In 2022, vehicle deliveries grew 40% year-over-year to 1.31M while production grew 47% year-over-year to 1.37M, Tesla said in a statement. Tesla's Q4 Model 3 and Y production was 419,088, its Model S and X was 20,613. 2. Chinese EV makers NIO (NIO), Li Auto (LI), and Xpeng (XPEV) also announced deliveries over the weekend. NIO said it delivered 15,815 vehicles in December, representing an increase of 50.8% year-over-year. NIO also said it delivered 40,052 vehicles in Q4, representing an increase of 60.0% year-over-year, and 122,486 vehicles in 2022 in total, increasing by 34.0% year-over-year. Meanwhile, XPeng said it delivered 11,292 Smart EVs to customers in December, representing a 94% increase over November. Total vehicle deliveries for Q4 reached 22,204. As of December 31, 2022, year-to-date deliveries were 120,757, representing a 23% increase year-over-year. Total cumulative deliveries reached 258,710 as of December 31, 2022. Lastly, Li Auto announced that the company delivered 21,233 vehicles in December 2022, representing an increase of 50.7% year over year. This brought the company's Q4 deliveries to 46,319, up 31.5% year over year. Total deliveries in 2022 increased by 47.2% year over year to 133,246. The cumulative deliveries of Li Auto vehicles reached 257,334 as of the end of December. 3. Southwest Airlines (LUV) returned to more normal operations this weekend, contending with some weather challenges as it sought to regain credibility with regulators and travelers following the carrier's meltdown over the holidays, The Wall Street Journal's Alison Sider reports. Southwest restored its full schedule Friday after slashing flying plans much of the week in an effort to regain its footing after the cascade of cancellations, the author notes. It scrapped just a few dozen flights Saturday and Sunday-less than 1% of what it had scheduled each day, according to FlightAware. 4. Disney's (DIS) "Avatar: The Way of Water" won this New Year's weekend with an estimated $86.3M for the four days for a domestic total of $444.4M as it crossed $1.4B in worldwide ticket sales on Monday. Overseas, the movie grossed an estimated $186.7M for the three-day weekend for a foreign cume of $956.9M. 5. Take-Two (TTWO) stock was down 43% in 2022, making it the group's worst performer, Jack Hough writes in this week's edition of Barron's. Now, the company is betting big on game demand in the coming years. Micron (MU) was also down 46% in 2022, as the semiconductor industry has swung from fierce demand and short supply to bloated supply and iffy demand, the author writes. But inventory digestion for memory could be relatively quick, too. On the streaming side, subscriber growth has fizzled, and companies have been spending lavishly on content, with investors turning nervous and Warner Bros. Discovery's (WBD) stock dropping 60% in 2022, Hough notes. However, surveys show that subscribers are shifting to cheaper ad-supported plans where they're offered. That could set up nicely for Warner.
|
TSLA | Hot Stocks12:29 EST Tesla reports Q4 deliveries of 405,278 on production of 439,701 - Tesla announced that in the fourth quarter, it produced 439,701 vehicles, 4% of which are subject to operating lease accounting, and delivered 405,278 vehicles. In 2022, vehicle deliveries grew 40% year-over-year to 1.31M while production grew 47% year-over-year to 1.37M, Tesla said in a statement. "We continued to transition towards a more even regional mix of vehicle builds which again led to a further increase in cars in transit at the end of the quarter," it added. Tesla's Q4 Model 3 and Y production was 419,088, its Model S and X was 20,613.
|
SLVM | Hot Stocks08:54 EST Sylvamo closes $160M purchase of uncoated freesheet paper mill - Sylvamo said it closed an agreement acquiring Stora Enso's uncoated freesheet paper mill in Nymolla, Sweden, for $160M subject to final net working capital and net debt adjustments.
|
ACI | Hot Stocks08:07 EST Albertsons granted expedited review of special dividend restraining order - Albertsons (ACI) announced the State of Washington Supreme Court has granted the company's motion to hold an expedited review of the temporary restraining order against its previously announced $6.85 per common share special dividend. The date for the review has been moved forward to January 17, having previously been set for February 9. Albertsons "continues to maintain that the claim brought by the Attorney General of the State of Washington, and the similar lawsuit brought by the Attorneys General of California, Illinois, and the District of Columbia, are meritless and provide no legal basis for preventing the payment of the Special Dividend. Albertsons' position has been supported by favorable rulings in both Circuit and District courts in the District of Columbia and a Washington State court," the company said in a statement. Albertsons proposed merger with Kroger (KR) is continuing through required regulatory review, it added.
|
CLBT CYBR | Hot Stocks07:08 EST Cellebrite names Zohar Tadmor-Eilat Chief People Officer - Cellebrite DI announced that Zohar Tadmor-Eilat (CLBT) has been named Chief People Officer, effective February 1. She succeeds Osnat Tirosh, who is leaving Cellebrite after ten years to pursue other career and professional growth opportunities. Prior to joining Cellebrite, Zohar served as the Global Vice President of Human Resources at CyberArk (CYBR).
|
VKTX ASCLF | Hot Stocks07:06 EST Ascletis says Viking Therapeutics complaints 'have no merit' - Ascletis Pharma (ASCLF) said it was informed on December 29, 2022, that Viking Therapeutics (VKTX) filed certain complaints against Ascletis, its founder Jinzi Jason WU and certain subsidiaries of Ascletis in connection with the drug candidates ASC41 and ASC43F. One complaint was made with the United States International Trade Commission and another complaint was made with the United States District Court, Southern District of California, San Diego Division, each covering similar allegations, the company said in a statement. As of this date, Viking has not yet served the complaints on Ascletis or raised the relevant allegations with Ascletis before filing of the complaints, the company added. From the publicly available allegations of Viking set out in the Complaints, Ascletis "believes that such allegations have no merit and will vigorously defend against the Complaints." It states, "ASC41 is an in-house developed oral tablet using Ascletis' own technologies and targeting thyroid hormone receptor beta for the treatment of non-alcoholic steatohepatitis; ASC43F is an in-house developed fixed-dose combination oral tablet using Ascletis' own technologies and with dual targets of thyroid hormone receptor beta and farnesoid X receptor for the treatment of NASH. Ascletis will closely monitor the above legal proceedings, while the business and operations of Ascletis and its subsidiaries remain as usual and normal."
|
WATT AMSSY | Hot Stocks06:59 EST Energous, ams announce agriculture sensor application collaboration - Energous (WATT) and ams OSRAM (AMSSY) announced a collaboration on a wirelessly powered multi-spectral light sensor for controlled-environment agriculture and vertical farming. The joint solution is based on the multi-channel AS7343 spectral sensor from ams OSRAM and the WattUp PowerBridge from Energous will be available for live demonstrations at the Energous booth at CES 2023 in Las Vegas, January 5-8.
|
ZH | Hot Stocks06:57 EST Zhihu announces resignation of CFO Wei Sun, names replacement - Zhihu announced that its board has appointed Henry Dachuan Sha as a Director and the Chief Financial Officer of the company, effective immediately. Sha will replace Wei Sun, who has tendered his resignation from the positions of Director and Chief Financial Officer to pursue other business endeavors. Prior to joining Zhihu, Sha served as the CFO of Quwan Holding between October 2020 and December 2022. From September 2017 to December 2019, Sha served as the CFO of Huya (HUYA).
|
LEGN | Hot Stocks06:54 EST Legend says China accepts ciltacabtagene New Drug Application - Legend Biotech announced that China's National Medical Products Administration has formally accepted its New Drug Application for ciltacabtagene autoleucel. This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 conducted in China, which evaluated the efficacy and safety of cilta-cel in adult patients with relapsed or refractory multiple myeloma who have received 3 or more prior lines of therapy, including a proteasome inhibitor and immunomodulatory drug, the company said in a statement. Ying Huang, Chief Executive Officer of Legend, said: "Meeting medical needs and serving patients around the world has always been the goal of Legend Biotech's innovative research and development. Cilta-cel has been approved for marketing in the United States and Japan and has received conditional marketing authorization in Europe. We look forward to the possibility of providing a new treatment option for appropriate patients with relapsed and refractory multiple myeloma in China."
|